GKIM
CYTK icon

GW&K Investment Management’s Cytokinetics CYTK Stock Holding History

GW&K Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78M Buy
916,107
+421,488
+85% +$30.3M 0.61% 41
2026
Q1 		$32.6M Buy
494,619
+22,256
+5% +$1.41M 0.29% 127
2025
Q4 		$30M Buy
472,363
+291,693
+161% +$18.1M 0.26% 155
2025
Q3 		$9.93M Buy
+180,670
New +$7.44M 0.09% 251

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GW&K Investment Management's CYTK Position: Q2 2026 in Review

GW&K Investment Management increased its Cytokinetics (CYTK) stake by 85% in Q2 2026, buying an estimated $30.3M and bringing the position to 916,107 shares worth $78M. The position accounts for 0.61% of the portfolio, ranked #41.

GW&K Investment Management first reported a position in CYTK in Q3 2025 and has held it in 4 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • GW&K Investment Management held 916,107 shares of Cytokinetics worth $78M as of Q2 2026.
  • GW&K Investment Management bought 421,488 Cytokinetics shares in Q2 2026, an estimated $30.3M.
  • Cytokinetics made up 0.61% of GW&K Investment Management's portfolio in Q2 2026, its #41 holding.
  • GW&K Investment Management first reported a position in Cytokinetics in Q3 2025 and has held it in 4 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.